Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

This study has been completed.
Sponsor:
Collaborator:
Statens Serum Institut
Information provided by (Responsible Party):
Aeras
ClinicalTrials.gov Identifier:
NCT02066428
First received: February 17, 2014
Last updated: February 18, 2014
Last verified: February 2014

February 17, 2014
February 18, 2014
November 2007
May 2009   (final data collection date for primary outcome measure)
Evaluate the safety of one or two injections of two AERAS 404 antigen amounts administered with three different amounts of adjuvant [ Time Frame: All subjects will be followed for safety and immunogenicity evaluations for 182 days. A total of eleven clinic visits are planned (excluding screening) for all subjects ] [ Designated as safety issue: Yes ]
Serious adverse events (SAE) will be collected on subjects throughout their participation in the study. Solicited and unsolicited AEs will be collected through 28 days after each vaccination.The safety profile of the different antigen/adjuvant treatment regimens will be described. Listings will be provided for all subjects with serious adverse events (SAE). All adverse events and clinically relevant laboratory results will be summarized across time points to examine the relationship between treatment regimens (i.e., number of doses and level of antigen/adjuvant) and key safety endpoints including number (percentage) of solicited and spontaneous adverse events and number (percentage) of subjects with newly abnormal post-vaccination laboratory values based on predefined toxicity criteria. Adverse events will also be summarized by severity and relationship to study vaccine by treatment regimen.
Same as current
Complete list of historical versions of study NCT02066428 on ClinicalTrials.gov Archive Site
Evaluate the immunogenicity of one or two injections of two AERAS 404 antigen amounts administered with three different amounts of adjuvant. [ Time Frame: all subjects will have immunology samples taken at 9 time points over 182 days ] [ Designated as safety issue: No ]
Assessment of immune response will be based on the percentage of CD4 and CD8 T cells producing any of three cytokines (interferon gamma, IFN-γ; tumor necrosis factor alpha, TNF-α; and/or interleukin-2, IL-2) or any combination of these three cytokines simultaneously in response to stimulation with two the antigenic peptide pools contains 85B and TB10.4 representing the entire amino acid sequences of mycobacterial antigens Ag85B and TB10.4, respectively. Responses will be measured by flow cytometry using a qualified intracellular cytokine staining (ICS) assay
Same as current
Not Provided
Not Provided
 
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection
A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection

Phase I, randomized, double blinded, Placebo-controlled, immunogenicity and dose-range finding study of AERAS-404 in Bacille Calmette-Guerin (BCG) healthy adult male and sterile females.

This ia a Phase I, randomized, placebo-controlled, double-blind study in three groups of healthy adult males or sterile females who are BCG-vaccinated, HIV-negative, and have no evidence of tuberculosis infection.

Sixty-four subjects assigned to one of eight treatment groups to receive one of four different antigen/adjuvant combinations of study vaccine, or placebo control. Within each study group, subjects will be randomized to receive either a single-dose antigen/adjuvant regimen of study vaccine (vaccination with study vaccine on Study Day 0 followed by vaccination with placebo control on Study Day 56) or a two-dose antigen/adjuvant regimen of study vaccine (vaccination with study vaccine on Study Days 0 and 56).

All subjects will be followed for safety and immunogenicity evaluations for 182 days.

The sample sizes specified for each study group were selected because they are judged to be adequate for preliminary safety and immunogenicity evaluations for a Phase I study rather than for statistical reasons. If no SAE are observed among 56 subjects receiving active study vaccine, an approximation to the upper 95% confidence bound on the rate of SAE occurrence would be 5.4%.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Tuberculosis
  • Biological: AERAS-404
    AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
    Other Name: H4
  • Biological: Placebo
    Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
    Other Name: Tris Buffered saline
  • Experimental: AERAS-404(50mcg H4/0nmol IC31) or Placebo
    1 dose
    Interventions:
    • Biological: AERAS-404
    • Biological: Placebo
  • Experimental: AERAS404 (50mcgH4/100nmol IC31) or Placebo
    1 dose
    Interventions:
    • Biological: AERAS-404
    • Biological: Placebo
  • Experimental: AERAS404 (50mcgH4/0nmol IC31) or Placebo
    2 dose
    Interventions:
    • Biological: AERAS-404
    • Biological: Placebo
  • Experimental: AERAS404 (150mcgH4/0nmol IC31) or Placebo
    1 dose
    Interventions:
    • Biological: AERAS-404
    • Biological: Placebo
  • Experimental: AERAS404 (50mcgH4/5000nmol IC31) or Placebo
    1 dose
    Interventions:
    • Biological: AERAS-404
    • Biological: Placebo
  • Experimental: AERAS404 (50mcgH4/500nmol IC31) or Placebo
    2 dose
    Interventions:
    • Biological: AERAS-404
    • Biological: Placebo
  • Experimental: AERAS404
    2 dose placebo
    Intervention: Biological: Placebo
  • Experimental: AERAS404 (50mcg H4/100nmol IC31) or Placebo
    2 dose
    Interventions:
    • Biological: AERAS-404
    • Biological: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
64
May 2009
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or female
  2. Age 18 through 50 years on Study Day 0
  3. Completed wriiten Informed Consent
  4. BCG vaccination at least 5 years ago,
  5. General good health, confirmed by medical history
  6. (BMI) between 19 and 33 (kg/m2)
  7. Has ability to complete follow-up period of 182 days as required
  8. Females must be physically incapable of conception
  9. Avoiding elective surgery for the duration of the study
  10. Stay in contact with the investigative site for the duration of the study
  11. Complete simultaneous enrollment in Aeras Vaccine Development Registry protocol

Exclusion Criteria:

  1. Acute illness on the day of randomization
  2. Oral temperature >=37.5 degree Celcius on the day of randomization
  3. Evidence of significant active infection
  4. Used immunosuppressive medication within 42 days before entry into the study
  5. Received immunoglobulin or blood products within 42 days before entry into the study
  6. Received any investigational drug therapy or investigational vaccine within 182 days
  7. Received inactivated influenza vaccine or inactivated tick-borne encephalitis vaccine within 14 days before entry into the study.
  8. Current chronic drug therapy including hormone replacement such as thyroxin, insulin, etc.
  9. History or laboratory evidence of any past, present or future possible immunodeficiency state which will include any laboratory indication of virus type 1 (HIV-1) infection
  10. History of allergic disease or reactions, including eczema.
  11. Previous medical history that may compromise safety of subject
  12. Evidence of new acute illness that may compromise safety of subject
  13. Evidence of chronic hepatitis
  14. Inability to discontinue daily medication except contraception
  15. History of alcohol or drug abuse within 2yrs
  16. Tobacco or cannabis smoking three
  17. Positive urine test for illicit drugs
  18. History or evidence of any systemic disease on physical examination
  19. History of active TB
  20. Shared residence within 1 year with an individual on anti-TB treatment
  21. All females: nursing
  22. Abnormal hemoglobin,hematocrit etc drawn within 36 hours prior to randomization
  23. Laboratory test evidence of Mtb infection
  24. History of positive tuberculin skin test within past 10 years
  25. Received a tuberculin skin test within 3 years
  26. History of autoimmune disease
Both
18 Years to 50 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT02066428
C-005-404
Yes
Aeras
Aeras
Statens Serum Institut
Study Director: Zhongkai SHI, MD Aeras
Principal Investigator: Jan Andersson, MD Karolinska Institutet
Aeras
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP